Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hemab Therapeutics Holdings, Inc. - Common Stock (NQ:COAG)

49.02 +3.45 (+7.57%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hemab Therapeutics Holdings, Inc. - Common Stock

News headline image
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board 
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans ↗
Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies... 
Via MarketBeat
News headline image
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Reports First Quarter 2026 Financial Results
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Hemab Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.